Daily Morning Note – 15 February 2022

Welcome to our Daily Morning Note from our Research team!


U.S. equity futures rose Tuesday and crude oil dipped as traders parsed geopolitical risks and worries about Federal Reserve monetary-policy tightening to fight inflation.

In Asia, markets looked set for a cautious start. Australian shares slipped, contracts for Japan were steady and those for Hong Kong fell. The S&P 500 notched a third straight drop Monday after a few rebound attempts, while the technology-heavy Nasdaq 100 closed with a small gain.

Treasuries sold off in the U.S. session as haven demand sparked by the Ukraine standoff eased. The yield curve flattened, flagging worries that looming Fed interest-rate hikes could choke economic growth. A dollar gauge rose.

The simmering Russia-Ukraine tensions are still keeping oil markets on edge. West Texas Intermediate edged back, it remained in sight of $95 a barrel after earlier scaling that mark for the first time since 2014.

Stocks to watch: Silverlake Axis, DBS

Top gainers & losers




Thai Beverage Public Company (ThaiBev) said on Monday (Feb 14) that it recorded an increase in sales revenue for its first quarter ended Dec 31, 2021, as the improving Covid-19 situation in Thailand drove sales growth in all business segments. In a business update on Monday (Feb 14), the group said that revenue for the 3-month period was up 7.4 per cent to 77.1 billion Thai baht (S$3.2 billion). Earnings before interest taxes, depreciation and amortisation (Ebitda) for the period was also 1.6 per cent higher year-on-year, at 14.7 billion Thai baht.

Wealth management platform iFast Corporation reported on Monday (Feb 14) a 5.5 per cent year-on-year increase in net profit for the fourth quarter ended Dec 31, 2021. Net profit for the 3-month period rose to S$7.2 million from S$6.8 million in the prior year period, as revenue grew 13.9 per cent to S$54.6 million. On a per-share basis, earnings for the quarter rose to S$0.026 from S$0.0251 a year earlier. iFast’s directors have proposed a final dividend of S$0.014 per share, an increase of 40 per cent on year from the previous final dividend.

Enterprise technology, software and services company Silverlake Axis reported on Monday (Feb 14) a jump in profit for its second quarter amid higher revenue. In a bourse filing, the mainboard-listed company said profit after tax for the 3 months ended Dec 2021 grew 72 per cent on year to RM59.6 million (S$19.2 million). This came as revenue for the quarter rose 29 per cent to RM206.5 million, with strong growth in project related revenue segments. Project-related revenue segments increased 110 per cent on year to RM56.6 million in the second quarter, the company said.

DBS sees itself in a strong position heading into a year of impending rate hikes, with loan growth and CASA (current account and savings account) ratios at their highest levels and asset quality improving as economies continue to rebound. On Monday (Feb 14), the lender reported a net profit of S$1.4 billion for the fourth quarter ended Dec 31, 2021, up 37 per cent from a year ago on higher fee income and lower allowances. Full-year net profit jumped 44 per cent to a record S$6.8 billion, though slightly below the S$6.9 billion estimate from analysts polled by Bloomberg. Return on equity also increased from 9.1 per cent to 12.5 per cent.

Transport operator ComfortDelGro, through its wholly-owned private bus company ComfortDelGro Bus, has clinched a close to S$20 million contract to operate its electric bus shuttle services in Nanyang Technological University (NTU). Its fleet of 20 electric buses will serve 4 routes on the NTU campus, starting from 7.30 am – 11 pm daily including public holidays, from September 2022 (see amendment note). This is the second electric bus contract the company has won, after it secured a S$30 million contract to operate its electric bus fleet in National University of Singapore in November 2021.

Construction and engineering group Civmec reported on Monday (Feb 14) a 50.1 per cent increase in net profit for its fiscal first half ended Dec 31, 2021, on the back of higher revenue. Net profit for the 6 month period rose to A$22.6 million, up from A$15 million in the same period a year earlier. On a per share basis, earnings had risen to A$0.045 from A$0.03 in the corresponding period previously. The board of Civmec declared an interim dividend of A$0.01, unchanged from the prior year period.


Texas Attorney General Ken Paxton filed a lawsuit against Meta on Monday, alleging the Facebook parent illegally collected biometric data on users without their consent. The suit makes claims similar to those made in a class action case Facebook settled for $650 million last year. That case alleged Facebook violated Illinois’ Biometric Information Privacy Act by storing data about people’s faces without their consent for its photo-tag suggestion tool. Facebook announced in November it would shut down its facial-recognition system that identified faces in photos and suggested that users tag them. The company said it would delete individual facial-recognition templates for more than 1 billion people.

The Food and Drug Administration’s plan to fast-track Pfizer’s Covid vaccine for children under 5 years old was delayed because of a “low number of cases overall in the clinical trial,” Dr. Scott Gottlieb told CNBC on Monday. “Most kids are not getting symptomatic Covid,” said the current Pfizer board member and former head of the FDA. “One case in one direction or another can tip the perception of the vaccine’s overall effectiveness.” “The FDA wanted to take the time for this data set to effectively settle down,” Gottlieb said on “Squawk Box.” “That point’s probably going to be after they’ve administered the third dose and have the data from that third dose.” He added, “At that point you’ll be able to get more of a fixed perception of the vaccine’s overall effectiveness” in that younger group, the only cohort not cleared in the U.S. for the shots.

Ukraine has requested a meeting with Russia within 48 hours as U.S. intelligence officials warn that a Russian invasion could begin this week. On Sunday evening, Ukrainian Foreign Minister Dmytro Kuleba said Russia had failed to respond to a request Ukraine had filed under the Vienna Document — a treaty signed by 56 member states aimed at maintaining military transparency across Europe — for a meeting. “Consequently, we take the next step,” Kuleba said in a statement. “We request a meeting with Russia and all participating states within 48 hours to discuss its reinforcement and redeployment along our border and in temporarily occupied Crimea.”

Britain’s tax watchdog has seized three non-fungible tokens, in what is thought to be the first seizure of NFTs by a U.K. law enforcement agency. Officials at Her Majesty’s Revenue and Customs say they seized the NFTs during an investigation into a suspected value-added tax (VAT) fraud case worth £1.4 million ($1.9 million). Three suspects have been arrested on suspicion of attempting to defraud the taxman. The suspects allegedly tried to claim back more VAT, which is a type of sales tax, than what they were owed, using a mix of stolen identities, unregistered phones and false invoices to hide their identities. The scheme involved 250 alleged fake companies, according to HMRC.

Source: SGX Masnet, The Business Times, Bloomberg, Channel NewsAsia, Reuters, CNBC, PSR

UG Healthcare Corporation Ltd – Stability and value creeping up

Recommendation: BUY (Upgraded), Last Done: S$0.27
Target Price: S$0.32, Analyst: Paul Chew

– 1H22 PATMI fell 67% YoY to S$21.2mn. Revenue/PATMI were within expectations at 52%/54% of our FY22e forecasts. Glove selling prices fell by more than 50% and glove production was disrupted in the three months of July to September 2021.

– We believe industry glove prices are still slipping in 1Q22, but at a slower pace of around 10% QoQ to US$20-25.

– We maintain our FY22e earnings forecast. Some stability is creeping up in glove selling prices. Any rebound in prices will remain elusive due to the huge influx of nitrile capacity, especially from China. Our target price is unchanged at S$0.32 and pegged at a 30% discount to the Big 4 glove makers. This implies 5x FY22e PE. We raise our recommendation from ACCUMULATE to BUY. We see value in the share price as the company is trading below its book value of 33.8 cents and 43% of the market capitalisation is net cash.

POEMS Podcast: Let the Money Talk

Recent Podcasts:

Keppel Corporation FY21 Results – SGX Company Insights Ep 50

Daily Morning Note – February 4, 2022

Microsoft Corporation 2Q22 Results – SGX Company Insights Ep 49

Visit www.stocksbnb.com to learn more!


Join our Phillip Securities Research Telegram channel for the latest update on our stock coverage!

Click the link to join: https://t.me/stocksbnb


Weekly Market Outlook: Amazon, FAANGM Monthly, BRC, SGX, SG Banking, ART, StarHub, Oxley, Singapore Weekly

Date: 14 February 2022

Click here for more on Market Outlook

Sign up for our webinars here, and be among the first to receive economy and market updates.

HK Reports – Read up on our Hong Kong reports here

Updates summarised in 3 minutes

Phillip Research in 3 minutes: #29

Keppel Corporation; Initiation

Click here for more videos on Phillip in 3 Mins

For any research-related matters, email: research@phillip.com.sg

For general enquiries, email: talktophillip@phillip.com.sg
or call 6531 1555.

Read the research report(s), available through the link(s) above, for complete information including important disclosures Important Information


The information contained in this email is provided to you for general information only and is not intended to create any binding legal relation. The information or opinions provided in this email do not constitute investment advice, a recommendation, an offer or solicitation to subscribe for, purchase or sell any investment product. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of this information. Investments are subject to investment risks including possible loss of the principal amount invested. The value of the product and the income from them may fall as well as rise.

You should obtain advice from a financial adviser before making a commitment to invest in any investment product or service. In the event that you choose not to obtain advice from a financial adviser, you should assess and consider whether the investment product or service is suitable for you before proceeding to invest.

Confidentiality Note

This e-mail and its attachment(s) may contain privileged or confidential information, which is intended only for the use of the recipient(s) named above. If you have received this message in error, please notify the sender immediately and delete all copies of it. If you are not the intended recipient, you must not read, use, copy, store, disseminate and/or disclose to any person this email and any of its attachment(s). PhillipCapital and its members will not accept legal responsibility for the contents of this message. Thank you for your cooperation.


Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you


This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  


Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com